Thymalin Research for Immunodeficiency
An evidence-based overview of research examining Thymalin in the context of immunodeficiency. This page synthesizes findings from peer-reviewed literature.
Research Summary
Thymalin has been used clinically in Russia since the 1970s for secondary immunodeficiencies. Russian studies report improvements in T-cell counts and function in immunocompromised patients. The 2020 in-vitro study demonstrated HSC differentiation into mature T-lymphocytes. However, Western clinical validation is absent.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Immunodeficiency
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Thymalin may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.